CELLINK, one of the first companies to emerge as a major global player in the bioprinting industry, is going to change its name to BICO. The new name reflects the Group’s strategic bio-convergence agenda and emphasizes that the company now comprises a Group consisting of several subsidiaries divided into three business areas.
In addition, the journey begins to, over time, build a world-famous company by unleashing the power and future potential of a new brand. The first step in the process for changing the name will be through the resolution at the Extraordinary General Meeting on August 6, 2021, and by amending the Articles of Association and thereafter register with the Swedish Companies Registration Office.
CELLINK has carried out extensive brand work in 2021. The aim has been to create a brand strategy that better reflects the Group’s development and to better harness the power, strength, and future potential of a new brand. An important component has been to further strengthen the alignment to the Group’s strategic bio convergence agenda. This has resulted in a proposal for a new Group name as well as new visual identity with a new logotype which is reflected in the new name, BIo COnvergence.
“In five years, we have built a world-leading group that offers something truly unique – namely a bio-convergence revolution. We believe in this concept so strongly that we decided to name the organization after it. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D printing with biology, we enable our customers to improve people’s health and lives for the better. We have always challenged and developed the industry. We will continue to do this in a new context since the new name releases even better opportunities to communicate our offering, our plans going forward, and how we contribute to create the health of the future”, says Erik Gatenholm, CEO.
The proposal to change the company’s name applies only to CELLINK AB (publ). The subsidiaries which are part of the Group will keep their names. No changes as a result of the name change will take place for employees within the Group regarding their employment. In the future, the name CELLINK will continue to be used by the wholly-owned subsidiary CELLINK Bioprinting AB which develops and sells bioprinters and consumables under the CELLINK brand.
If the name change is approved at the extraordinary general meeting, it also means that the company changes the ticker from CLNK to BICO. Otherwise, there are no changes to the company’s financial instruments.